NCT06222476View on ClinicalTrials.gov

Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.

NANot yet recruitingINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2026

Conditions

Diabetic Nephropathy Type 2

Interventions

DRUG

Dorzagliatin

Dorzagliatin will be initiated and maintained at 75mg twice a day

DRUG

Gliclazide

Gliclazide will be initiated and maintained at 30mg once a day

Trial Locations (1)

210008

Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing

All Listed Sponsors

lead

Yan Bi

OTHER

NCT06222476 - Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study. | Biotech Hunter | Biotech Hunter